| 87.895 0.565 (0.65%) | 12-05 10:04 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 106.11 | 1-year : | 123.93 |
| Resists | First : | 90.84 | Second : | 106.11 |
| Pivot price | 86.52 |
|||
| Supports | First : | 81.32 | Second : | 75.44 |
| MAs | MA(5) : | 86.35 |
MA(20) : | 85.71 |
| MA(100) : | 67.76 |
MA(250) : | 0 | |
| MACD | MACD : | 2.7 |
Signal : | 3.1 |
| %K %D | K(14,3) : | 58 |
D(3) : | 48.6 |
| RSI | RSI(14): 62 |
|||
| 52-week | High : | 93.25 | Low : | 33.7 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ PTGX ] has closed below upper band by 31.3%. Bollinger Bands are 21.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 88.25 - 88.67 | 88.67 - 89.05 |
| Low: | 84.09 - 84.58 | 84.58 - 85.03 |
| Close: | 86.52 - 87.33 | 87.33 - 88.06 |
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Wed, 03 Dec 2025
Prudential Financial Inc. Has $4.28 Million Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Wed, 03 Dec 2025
Legal & General Group Plc Grows Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Wed, 03 Dec 2025
Capital Fund Management S.A. Acquires New Holdings in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Wed, 03 Dec 2025
Protagonist Therapeutics (NASDAQ:PTGX) Nasdaq Futures Therapeutic Edge - Kalkine Media
Tue, 02 Dec 2025
Does Protagonist Therapeutics Offer Value After Major Pipeline Updates and Triple Digit 2024 Gains? - simplywall.st
Sun, 30 Nov 2025
Protagonist Therapeutics (PTGX) Price Target Increased by 16.48% to 91.65 - MSN
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 63 (M) |
| Shares Float | 50 (M) |
| Held by Insiders | 1 (%) |
| Held by Institutions | 115.5 (%) |
| Shares Short | 5,580 (K) |
| Shares Short P.Month | 6,310 (K) |
| EPS | 0.66 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 10.34 |
| Profit Margin | 21.9 % |
| Operating Margin | -985.2 % |
| Return on Assets (ttm) | 1.8 % |
| Return on Equity (ttm) | 7.8 % |
| Qtrly Rev. Growth | 0.8 % |
| Gross Profit (p.s.) | 3.34 |
| Sales Per Share | 3.34 |
| EBITDA (p.s.) | 0.32 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 65 (M) |
| Levered Free Cash Flow | 53 (M) |
| PE Ratio | 133.45 |
| PEG Ratio | 0 |
| Price to Book value | 8.51 |
| Price to Sales | 26.32 |
| Price to Cash Flow | 84.11 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|